e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension
Y. Tamura, M. Kuwana, K. Inoue, T. Ono, M. Takei, T. Yamamoto, M. Kataoka, M. Sano, T. Satoh, K. Fukuda (Tokyo, Japan)
Source:
Annual Congress 2012 - Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models
Session:
Pulmonary circulation: clinical diagnosis, treatment, end-points and animal models
Session type:
Thematic Poster Session
Number:
962
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Tamura, M. Kuwana, K. Inoue, T. Ono, M. Takei, T. Yamamoto, M. Kataoka, M. Sano, T. Satoh, K. Fukuda (Tokyo, Japan). Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. Eur Respir J 2012; 40: Suppl. 56, 962
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005
Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension?
Source: Eur Respir J 2016; 48: 1265-1267
Year: 2016
Gamma-Glutamyltransferase in pulmonary hypertension: A reliable biomarker?
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020
IL-6 in pulmonary hypertension: why novel is not always best
Source: Eur Respir J, 55 (4) 2000314; 10.1183/13993003.00314-2020
Year: 2020
Novel biomarkers in idiopathic pulmonary arterial hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Pentraxin 3 as a novel biomarker of inflammation in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
The role of the biomarker and the genetic polymorphism of endothelin-1 in pulmonary arterial hypertension among Egyptians
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Inflammatory biomarkers in patients with COPD and pulmonary hypertension (PH).
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension and their relationship with right ventricular structure and function
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Characteristics of idiopathic pulmonary arterial hypertension (IPAH) and PAH associated with connective tissue disease (APAH-CTD) patients in PROSPECT
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
CXCL12 as a potential disease marker for pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary hypertension
Year: 2010
Genetics of pulmonary hypertension: from bench to bedside
Source: Eur Respir J 2002; 20: 741-749
Year: 2002
Screening for biomarkers in pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology
Year: 2012
Circulating microRNA signature and its novel involvement in pathogenesis of chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH
Year: 2012
Analysis of miRNA profile in circulating microparticles of patients with pulmonary arterial hypertension
Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH
Year: 2015
Human β-defensin 2 and interleukin-8 as potential serum markers of pulmonary emphysema
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
Source: Eur Respir J 2008; 31: 343-348
Year: 2008
The interleukin 13 receptor system is altered in pulmonary arterial hypertension
Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling
Year: 2006
Expression of fetal genes in pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension and fibrosis: novel mechanisms
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept